Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Abemaciclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Abemaciclib as a study intervention. Browse Abemaciclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
188
Shown on this page
12
Current sort
Recently updated
Therapy scope
Abemaciclib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Abemaciclib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 169–180 of 188 matching trials for Abemaciclib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 1Phase 2 Interventional Results available

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

NCT03655444
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Abemaciclib, Nivolumab, Tumor biopsy, Peripheral blood, EORTC QLQ-30
Drug · Procedure · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 24, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

NCT02079636
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung
Interventions
Abemaciclib, Pemetrexed, Gemcitabine, Ramucirumab, LY3023414, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Fayetteville, Arkansas • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 24, 2026, 8:12 PM EDT
Withdrawn Early Phase 1 Interventional

Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma

NCT04220892
View directory record Official record
Conditions
High Grade Glioma
Interventions
Pembrolizumab, Pemetrexed, Abemaciclib
Drug
Lead sponsor
Jose Carrillo
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 24, 2026, 8:12 PM EDT
Withdrawn Early Phase 1 Interventional

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

NCT04088032
View directory record Official record
Conditions
Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
Abemaciclib, durvalumab and aromatase inhibitor
Drug
Lead sponsor
Alison Stopeck
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 24, 2026, 8:12 PM EDT
Withdrawn Phase 2 Interventional

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

NCT04272645
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abemaciclib 200 MG, Atezolizumab 1200 MG in 20 ML Injection, Abemaciclib 150 MG
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 24, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT02441946
View directory record Official record
Conditions
Breast Cancer, Hormone Receptor Positive Tumor, Early-Stage Breast Carcinoma
Interventions
Abemaciclib, Loperamide, Anastrozole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Bakersfield, California • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 24, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

NCT02102490
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
27
States / cities
Sedona, Arizona • Tucson, Arizona • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 24, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

NCT02981342
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Abemaciclib, LY3023414, Gemcitabine, Capecitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
New Haven, Connecticut • Peoria, Illinois • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 24, 2026, 8:12 PM EDT
Withdrawn Phase 4 Interventional

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

NCT03988114
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
70
States / cities
Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 24, 2026, 8:12 PM EDT
Completed Phase 1 Interventional

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

NCT02745769
View directory record Official record
Conditions
Advanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
Interventions
Ramucirumab, Merestinib, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 24, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment

NCT02387814
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 24, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2835219 in Healthy Participants

NCT02059148
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2835219
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 24, 2026, 8:12 PM EDT

About this Abemaciclib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Abemaciclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Abemaciclib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Abemaciclib.